866-997-4948(US-Canada Toll Free)

Ovarian Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Published By :

GlobalData

Published Date : Dec 2010

Category :

Ovarian Cancer

No. of Pages : 55 Pages


GlobalData, the industry analysis specialist, has released its new report, “Ovarian Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global ovarian cancer market. The report identifies the key trends shaping and driving the global ovarian cancer market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. 

 

Most importantly, the report provides valuable insights on the pipeline products within the global ovarian cancer sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. GlobalData forecasts the global varian cancer therapeutics market to grow at 16.2% annually for the next eight years to reach $1.77 billion by 2017. It was valued at $510m in 2009. This significant growth is primarily attributed to the high prescription rates of multiple lines of chemotherapeutic drugs. In addition, the successful launch of some of the molecular targeted therapies, such as Avastin and Farletuzumab, which are currently in Phase III trials, may significantly stimulate market growth in the near future. However, the low diagnosis rate and decreasing incidence of the disease will continue to be a barrier for market growth. 

 

Scope

 

The report provides information on the key drivers and challenges of the ovarian cancer market. Its scope includes:

 

  • Annualized global ovarian cancer market revenues data from 2001 to 2009, forecast for eight years to 2017.
  • Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as Angiogenesis inhibitors, PAR P inhibitors, Kinase inhibitors, Antifolate, Immuno regulatory.
  • Analysis of the current and future competition in the global ovarian cancer market. Key market players covered are Abbott, Pfizer, Novartis AG, Lpath Inc. and F. Hoffmann La Roche Ltd.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the ovarian cancer therapeutics market.

Reasons to buy

 

The report will enhance your decision making capability. It will allow you to:

 

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global ovarian cancer market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global ovarian cancer market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
  • What’s the next big thing in the global ovarian cancer market landscape? - Identify, understand and capitalize.

Table of Contents

1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 4

2 Ovarian Cancer Therapeutics Introduction 5
2.1 Symptoms 5
2.2 Diagnosis 5
2.3 GlobalData Pipeline Report Guidance 6

3 Ovarian Cancer Therapeutics Market Characterization 7
3.1 Overview 7
3.2 Ovarian Cancer Therapeutics Market Size 7
3.3 Ovarian Cancer Therapeutics Market Forecast and CAGR 7
3.4 Drivers and Barriers for the Ovarian Cancer Therapeutics 9
3.4.1 Drivers for Ovarian Cancer Therapeutics 9
3.4.2 Barriers for Ovarian Cancer Therapeutics 9
3.5 Opportunity and Unmet Need 10
3.6 Key Takeaway 11

4 Ovarian Cancer Therapeutics Competitive Assessment 12
4.1 Overview 12
4.2 Strategic Competitor Assessment 12
4.3 Product Profile for the Major Marketed Products in Ovarian Cancer Therapeutics 13
4.3.1 Alkylating Agents (Carboplatin, Cisplatin, Melphalan and Altretamine) 13
4.3.2 Anthracyclines-Doxorubicin (Doxil, Adriamycin) 13
4.3.3 Taxol (paclitaxel) 14
4.3.4 Gemzar (gemcitabine) 14
4.3.5 Hycamtin (topotecan hydrochloride) 16
4.4 Key Takeaway 19

5 Ovarian Cancer Therapeutics Pipeline Assessment 20
5.1 Overview 20
5.2 Strategic Pipeline Assessment 20
5.2.1 Technology Trends Analytic Framework 20
5.3 Ovarian Cancer Therapeutics Promising Drugs Under Clinical Development 22
5.4 Molecule Profile for Promising Drugs Under Clinical Development for Ovarian Cancer 23
5.4.1 Avastin (RG435, Bevacizumab) 23
5.4.2 Farletuzumab (MORAb-003) 25
5.4.3 Abagovomab 25
5.4.4 Opaxio 26
5.4.5 Telcyta 27
5.4.6 Karenitecin (BNP 1350) 28
5.5 Ovarian Cancer Therapeutics Clinical Pipeline by Mechanism of Action 29
5.6 Ovarian Cancer Therapeutics Pipeline Pipeline by Clinical Phases of Development 29
5.6.1 Ovarian Cancer Therapeutics Regulatory and Phase III Clinical Pipeline 30
5.6.2 Ovarian Cancer Therapeutics Phase II Clinical Pipeline 31
5.6.3 Ovarian Cancer Therapeutics Phase I Clinical Pipeline 35
5.6.4 Ovarian Cancer Therapeutics Pre-clinical Pipeline 37
5.7 Key Takeaway 38

6 Ovarian Cancer Therapeutics Implications for Future Market Competition 39

7 Ovarian Cancer Therapeutics Future Players in Ovarian Cancer Therapeutics Market 41

7.1 Introduction 41
7.2 F. Hoffmann-La Roche Ltd/ Genentech, Inc. 41
7.2.1 Overview 41
7.2.2 Business Description 42
7.2.3 Oncology Portfolio 42
7.3 BioNumerik Pharmaceuticals 43
7.3.1 Overview 43
7.3.2 Oncology Portfolio 43
7.4 Telik, Inc. 44
7.4.1 Overview 44
7.4.2 Business Description 44
7.4.3 Oncology Products Portfolio 44
7.5 Morphotek, Inc. (Subsidiary of Eisai Co., Ltd.) 45
7.5.1 Overview 45
7.5.2 Oncology Products Portfolio 45
7.6 Cell Therapeutics Inc. 46
7.6.1 Business Description 46
7.7 Menarini Group 47
7.7.1 Overview 47
7.7.2 Business Description 47
7.7.3 Ovarian Cancer Pipeline Product Portfolio 48

8 Ovarian Cancer Therapeutics Appendix 49
8.1 Market Definitions 49
8.2 Abbreviations 49
8.3 Research Methodology 50
8.3.1 Coverage 51
8.3.2 Secondary Research 51
8.3.3 Forecasting 51
8.3.4 Primary Research 53
8.3.5 Expert Panel Validation 54
8.4 Contact Us 54
8.5 Disclaimer 54
8.6 Sources 54

List of Table


Table 1: Ovarian Cancer, Classification and Treatment Protocol Stages 6
Table 2:Ovarian Cancer Therapeutics, Global , Revenue ($m), 2001-2009 8
Table 3: Ovarian Cancer Therapeutics, Global, Forecast ($m), 2009-2017 8
Table 4: Ovarian Cancer Therapeutics , Gemzar Adverse Reactions 15
Table 5: Ovarian Cancer Therapeutics , Hycamtin Adverse Reactions 17
Table 6: Major Marketed Product Comparison in Ovarian Cancer Therapeutics Market, 2010 18
Table 7: Ovarian Cancer Therapeutics Promising Drugs Under Clinical Development, 2010 22
Table 8: Ovarian Cancer Therapeutics Regulatory and Phase III Clinical Pipeline, 2010 30
Table 9: Ovarian Cancer Therapeutics Phase II Clinical Pipeline, 2010 31
Table 10: Ovarian Cancer Therapeutics Phase I Clinical Pipeline, 2010 35
Table 11: Ovarian Cancer Therapeutics Pre-clinical and Discovery Pipeline, 2010 37
Table 12: F. Hoffmann-La Roche Ltd/Genentech, Inc. Oncology Pipeline Products, 2010 42
Table 13: F. Hoffmann-La Roche Ltd/Genentech, Inc. Ovarian Cancer Pipeline Products, 2010 42
Table 14: BioNumerik Pharmaceuticals, Inc. Oncology Pipeline Products, 2010 43
Table 15: BioNumerik Pharmaceuticals, Inc. Ovarian Cancer Pipeline Products, 2010 43
Table 16: Telik, Inc. Oncology Pipeline Products, 2010 44
Table 17: Telik, Inc. Ovarian Cancer Pipeline Products, 2010 45
Table 18: Morphotek/Eisai Oncology Pipeline Products, 2010 45
Table 19: Morphotek/Eisai Ovarian Cancer Pipeline Products, 2010 46
Table 20: Cell Therapeutics, Inc. Oncology Pipeline Products, 2010 47
Table 21: Cell Therapeutics, Inc. Oncology Pipeline Products, 2010 47
Table 22: Menarini Group Ovarian Cancer Pipeline Products, 2010 48

List of Chart


Figure 1: Ovarian Cancer Therapeutics , Global, Revenue ($m), 2001-2009 7
Figure 2: Ovarian Cancer Therapeutics, Global, Forecast ($m), 2009-2017 8
Figure 3: Opportunity and Unmet Need in the Ovarian Cancer Therapeutics , 2010 10
Figure 4: Strategic Competitor Assessment of the Major Marketed Products in Ovarian Cancer, 2010 13
Figure 5: Technology Trends Analytic Framework of the Ovarian Cancer Therapeutics Pipeline, 2010 21
Figure 6: Technology Trends Analytic Framework of the Ovarian Cancer Therapeutics Pipeline Description, 2010 21
Figure 7: Ovarian Cancer Therapeutics Clinical Pipeline by Mechanism of Action, 2010 29
Figure 8: Ovarian Cancer Therapeutics Pipeline by Phase of Clinical Development, 2010 29
Figure 9: Implications for Future Market Competition in the Ovarian Cancer, 2010 39
Figure 10: Ovarian Cancer Therapeutics Clinical Pipeline by Company, 2010 41
Figure 11: GlobalData Market Forecasting Model 53

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *